Your browser doesn't support javascript.
loading
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.
Goll, Johannes B; Jain, Aarti; Jensen, Travis L; Assis, Rafael; Nakajima, Rie; Jasinskas, Algis; Coughlan, Lynda; Cherikh, Sami R; Gelber, Casey E; Khan, S; Huw Davies, D; Meade, Philip; Stadlbauer, Daniel; Strohmeier, Shirin; Krammer, Florian; Chen, Wilbur H; Felgner, Philip L.
Afiliación
  • Goll JB; The Emmes Company, LLC, Rockville, MD, USA.
  • Jain A; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA.
  • Jensen TL; The Emmes Company, LLC, Rockville, MD, USA.
  • Assis R; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA.
  • Nakajima R; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA.
  • Jasinskas A; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA.
  • Coughlan L; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Cherikh SR; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Gelber CE; The Emmes Company, LLC, Rockville, MD, USA.
  • Khan S; The Emmes Company, LLC, Rockville, MD, USA.
  • Huw Davies D; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA.
  • Meade P; Vaccine R&D Center, Department of Physiology and Biophysics, University of California-Irvine, Irvine, CA, USA.
  • Stadlbauer D; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA.
  • Strohmeier S; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA.
  • Krammer F; Moderna Inc., Cambridge, MA, USA.
  • Chen WH; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA.
  • Felgner PL; Department of Microbiology, Icahn School of Medicine at Mount. Sinai, New York City, NY, USA.
NPJ Vaccines ; 7(1): 103, 2022 Aug 30.
Article en En | MEDLINE | ID: mdl-36042229
Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Vaccines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos